These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 6459385)

  • 21. Immune responses to weakly immunogenic murine-leukemia-virus-induced tumors. VIII. Characterization of suppressor cells.
    Deutsch O; Devens B; Naor D
    Isr J Med Sci; 1980 Jul; 16(7):538-44. PubMed ID: 6447123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus.
    Wood GW
    Cancer Res; 1976 Dec; 36(12):4552-7. PubMed ID: 1000500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigenic specificities of the cellular immune response of C57BL/6 mice to the Moloney leukemia/sarcoma virus complex.
    Enjuanes L; Lee JC; Ihle JN
    J Immunol; 1979 Feb; 122(2):665-74. PubMed ID: 84033
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of accessory cells in the induction of a secondary cytotoxic response to Moloney murine sarcoma virus-induced tumors.
    Biasi G; Saggin L; Dazzi F; De Rossi A; Collavo D
    J Immunol; 1983 Mar; 130(3):1447-50. PubMed ID: 6185589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Further evidence for the involvement of thymus-processed lymphocytes in syngeneic tumor cell cytolysis.
    Plata F; Gomard E; Leclerc JC; Levy JP
    J Immunol; 1973 Sep; 111(3):667-71. PubMed ID: 4542607
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of adhesion molecules in the immune reaction to M-MSV-induced tumors.
    Rosato A; Bronte V; Mandruzzato S; Zambon A; Calderazzo F; Biasi G; Zanovello P; Collavo D
    Int J Cancer Suppl; 1992; 7():24-7. PubMed ID: 1385341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells.
    Lamon EW; Whitten HD; Skurzak HM; Andersson B; Lidin B
    J Immunol; 1975 Nov; 115(5):1288-94. PubMed ID: 1080777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural suppressor cell inhibiting T killer responses against retroviruses: a model for self tolerance.
    Tilkin AF; Bègue B; Gomard E; Levy JP
    J Immunol; 1985 Apr; 134(4):2779-82. PubMed ID: 3156190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal analysis of the T lymphocyte response to murine sarcoma virus-induced tumors.
    Brunner KT; Weiss A; Cerottini JC; MacDonald HR
    Transplant Proc; 1982 Sep; 14(3):556-8. PubMed ID: 6217605
    [No Abstract]   [Full Text] [Related]  

  • 30. Mechanisms of leukemogenesis. I. Generation of autoreactive lymphocytes in response to a murine leukemia virus.
    Schenk PJ; Howe ML
    J Immunol; 1979 May; 122(5):1874-80. PubMed ID: 221580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune response to Moloney murine leukemia virus nonviral, tumor-associated antigens fails to provide in vivo tumor protection.
    Jiang D; Flyer DC
    J Immunol; 1992 Feb; 148(3):974-80. PubMed ID: 1730885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of effector lymphocytes associated with immunity to murine sarcoma virus (MSV) induced tumors. I. Physical properties of cytolytic T lymphocytes generated in vitro and of their immediate progenitors.
    Plata R; MacDonald HR; Engers HD
    J Immunol; 1976 Jul; 117(1):52-8. PubMed ID: 180182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence and specificity of accessory cell impairment in M-MuLV neonatally injected mice.
    Biasi G; Saggin L; Dazzi F; Collavo D
    Transplant Proc; 1983 Dec; 15(4):2125-7. PubMed ID: 6608813
    [No Abstract]   [Full Text] [Related]  

  • 34. Induction of Moloney murine sarcoma virus tolerance in adult mice by anti-CD4 monoclonal antibody treatment.
    Biasi G; Mazzocchi M; Facchinetti A; Panozzo M; Zanovello P; Collavo D; Chieco-Bianchi L
    Cancer Res; 1990 Sep; 50(17 Suppl):5703S-5706S. PubMed ID: 2167167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo.
    Leclerc JC; Cantor H
    J Immunol; 1980 Feb; 124(2):851-4. PubMed ID: 6243333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of gp70-specific suppressor T-cells in mice inoculated with virus-producing tumor cells.
    Bluestone JA; Lopez C
    J Natl Cancer Inst; 1982 Oct; 69(4):953-9. PubMed ID: 6214655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells.
    Brunner KT; MacDonald HR; Cerottini JC
    J Immunol; 1980 Apr; 124(4):1627-34. PubMed ID: 6154076
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunologic mechanisms in the pathogenesis of virus-induced leukemia. IV. Mechanism of target cell recognition by autoreactive thymocytes.
    Proffitt MR; Kozak C; de la Motte C; Caulfield MJ
    J Immunol; 1985 Jun; 134(6):4244-9. PubMed ID: 3872912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of alpha-fetoprotein on Moloney sarcoma virus oncogenesis: evidence for generation of antigen nonspecific suppressor T cells.
    Gershwin ME; Castles JJ; Ahmed A; Makishima R
    J Immunol; 1978 Dec; 121(6):2292-8. PubMed ID: 82580
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic control of sensitivity to moloney leukemia virus in mice. VI. Involvement of virus-specific T helper cells collaborating with B cells.
    Boyer B; Debré P; Seman M; Zilberfarb V; Lévy JP
    Eur J Immunol; 1982 Aug; 12(8):692-7. PubMed ID: 6216112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.